Novo Nordisk A/S should conduct more studies before its long-acting insulin icodec can be approved for use in type 1 diabetics, a majority of US Food and Drug Administration advisory committee members said on 24 May.
Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel
The Endocrinologic and Metabolic Drugs Advisory Committee majority says new studies should validate the proposed risk mitigation measures before approval for T1D.
